A Composite 18F-Fdg Pet/Ct and Her2 Tissue-Based Biomarker to Predict Response to Neoadjuvant Pertuzumab and Trastuzumab in Her2-Positive Breast Cancer (Tbcrc026)
Breast (Edinburgh, Scotland)(2025)
Key words
18F-FDG PET/CT,HER2-Biomarkers,Breast cancer,Neoadjuvant
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined